PureTech Health 주식 가격. PRTC - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

16.7088

매수가

17.00

매도가

24.62

거래량

516

16.7088 일간 변동폭 18.31

0.00 52주 범위 0.00

market_cap

400.044M

전일 종가

17.835

개장가

16.7088

최근 거래 시간

17.945

마지막 거래 시간

재정 규모

US$ 8,622

VWAP

16.7088

평균 볼륨(3m)

발행 주식

23,942,131

배당수익률

주가수익률

-0.48

주당순이익(EPS)

-2.74

매출

65.12M

순이익

-65.7M

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines ... PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, neurological & neuropsychological disorders, among others. It operates in following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of society's healthcare needs. 더 보기

섹터

Home Health Care Services

산업

Home Health Care Services

웹사이트

www.puretechhealth.com

본부

London, Gbr

설립됨

PureTech Health PLC is listed in the Home Health Care Services sector of the 나스닥 with ticker PRTC. The last closing price for PureTech Health was US$17.84. Over the last year, PureTech Health shares have traded in a share price range of US$ 0.00 to US$ 0.00.

PureTech Health currently has 23,942,131 shares in issue. The market capitalisation of PureTech Health is US$427.01 million. PureTech Health has a price to earnings ratio (PE ratio) of -0.48.

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied...

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and...

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients...

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Appoints UBS as UK Corporate Broker

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate...

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and...

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included in a planned Phase 2b study in major depressive...

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating...

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Lead Independent Director at Microsoft and former Group Worldwide Chair for Johnson & Johnson brings extensive experience in life sciences...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

PRTC - Frequently Asked Questions (FAQ)

What is the current PureTech Health share price?

The current share price of PureTech Health is US$ 16.7088

How many PureTech Health shares are in issue?

PureTech Health has 23,942,131 shares in issue

What is the market cap of PureTech Health?

The market capitalisation of PureTech Health is USD 427.01M

What is the 1 year trading range for PureTech Health share price?

PureTech Health has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of PureTech Health?

The price to earnings ratio of PureTech Health is -0.48

What is the cash to sales ratio of PureTech Health?

The cash to sales ratio of PureTech Health is 0.48

What is the reporting currency for PureTech Health?

PureTech Health reports financial results in USD

What is the latest annual turnover for PureTech Health?

The latest annual turnover of PureTech Health is USD 65.12M

What is the latest annual profit for PureTech Health?

The latest annual profit of PureTech Health is USD -65.7M

What is the registered address of PureTech Health?

The registered address for PureTech Health is C/O TMF GROUP, 13TH FLOOR, ONE ANGEL COURT, LONDON, EC2R 7HJ

What is the PureTech Health website address?

The website address for PureTech Health is www.puretechhealth.com

Which industry sector does PureTech Health operate in?

PureTech Health operates in the HOME HEALTH CARE SERVICES sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
PSTVPlus Therapeutics Inc	US$ 1.37 (168.10%)	357.75M
SAGSAG Holdings Ltd	US$ 1.15 (70.37%)	126.65M
OPTNOptiNose Inc	US$ 9.15 (52.50%)	2.17M
RGCRegencell Bioscience Holdings Ltd	US$ 44.06 (43.19%)	1.23M
NAOVNanoVibronix Inc	US$ 4.45 (36.50%)	1.06M
ELEVElevation Oncology Inc	US$ 0.2809 (-41.21%)	18.19M
BHILBenson Hill Inc	US$ 0.3969 (-38.50%)	1.47M
ADAPAdaptimmune Therapeutics PLC	US$ 0.28 (-37.65%)	14.05M
XHLDTEN Holdings Inc	US$ 0.99761 (-37.26%)	15.3M
LSELeishen Energy Holding Company Ltd	US$ 8.28 (-33.76%)	606.21k
PSTVPlus Therapeutics Inc	US$ 1.37 (168.10%)	357.75M
NVDANVIDIA Corporation	US$ 118.53 (0.86%)	247.95M
AGMHAGM Group Holdings Inc	US$ 0.077 (6.94%)	162.81M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8.16 (0.25%)	147.13M
SAGSAG Holdings Ltd	US$ 1.15 (70.37%)	126.65M

Ayock 2 분 전

The Public Service Loan Forgiveness (PSLF) program, which allows for student loan forgiveness after 10 years of public service, was established by Congress in 2007 and signed into law by President George W. Bush.

The College Cost Reduction and Access Act of 2007:
This act, sig

NYBob 2 분 전

Alberta PREMIER WALKS OUT Of Meeting After Carney’s SHOCKING Demand On Oil Exports
Canada Now

]yt[0DIBI-JAEjQ[/yt]

https://www.youtube.com/watch?v=0DIBI-JAEjQ

JUST NOW: Mark Carney Faces JA!L TIME – CAUGHT RED-HANDED In SHOCKING Poll Rigging Scan

MMY

MrMyers 3 분 전

Thanks for post your DD. Every encouraging article!

GTCH

Ayock 5 분 전

Biden Administration Announces 'Final' Student Loan Debt Relief Approvals
By Maria Carrasco, NASFAA Staff Reporter

With just a few days until the incoming Trump administration takes office, the Biden administration on Thursday announced its "final" approvals of student loan for

arizona1 9 분 전

https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:lgi3th7hikifyf2srdf5jncj/bafkreig43n656b55exn5jk6e4ec5ptsh2jrrt2t7obm5zwm2fjz3h6ktli@jpeg

uber darthium 11 분 전

Kool aid- he’s gonna need all that revenue from his front loaded shares to pay his legal fees when justice catches up with him…in the very near future I hear

Just my opinion

SPZI

overbore 11 분 전

Haywood is a stock brocker in Canada. They have helped facilitate US investors participate in the private placement events First Mining has offered. It becomes complicated with the legend removal of the warrants and they make it very easy. I've used them and would highly recommend. Very curious if

FFMGF

PepperJacked 12 분 전

I want everyone to see how mon and his minions operates by taking pieces of a report and then purposely leaves out the rest to deceive the reader of IFUS. He should be ashamed of himself. Here is the rest of that portion of the report that mon purposely left out. You tell me who is the deceiver here

IFUS

blownaccount9 12 분 전

I’m not a fan. This doesn’t have to be complicated just f’ing release them. No one is complaining that they don’t make enough money. The way Freddie is growing I think they are more valuable and I doubt they get compensated properly in event of combination.

FNMA

GoodGuyBill 13 분 전

No, if you think management is incompetent, you shouldn't send thank you letters to management and load up on share shares (that's what people who believe in NWBO/DCVAX-L/Linda Powers would do). Instead, you should divest, take you money and invest it in companies that you feel are more competent an

NWBO

redspeed 13 분 전

Moon Equity Holdings Corp. Announces Strategic Investment in ShieldCom
Press Release | 01/29/2025

Moon Equity Holdings Corp. Announces Decision Not to Pursue Investment in ShieldCom
Press Release | 02/11/2025

Interesting, that was quicker then the others.

MONI

thecrusher2011 14 분 전

My standards for truth obviously make me a bad person.

arizona1 14 분 전

I also logged into my SS account, although I needed to change my password. uggh! I printed out my latest statement since I'm going month to month always wondering.

rooster 15 분 전

I love how global climate change is suddenly over because Elon is helping our government weed out waste and fraud ! Hahshshahaha

RDY2ROCK 15 분 전

Hello from the ROK Brother Sterling!

Yes Sir....2025 looking to be a real sweet year for us SPZI / JP3E SH's!

It's been a real long couple of weeks and this PR made my morning! Outstanding and Gomapseumnida Mr. Park! YESSSSSS!!!!
https://www.otcmarkets.com/stock/

SPZI

TightCoil 17 분 전

Fannie and Freddie were Siblings, Oh, Lawdy, how they could Sible
OK, what are the latest
Boom Booms in a Nutshell? Please

FNMA

JMCK6193 18 분 전

Same here RIO

NXPL

TexasMarvL 18 분 전

Haywood Capital bought Osisko maybe 15 or 20 times. I lost count. I wonder what percentage of Osisko they owned by the time it sold?

FFMGF

JMCK6193 19 분 전

That's funny, I just ate Taco Bell 🔔 couple hours ago 😅

NXPL

StockItOut 20 분 전

That mean you post to encourge us to buy or sucker in folks to lose their money? lol .
Posting for no gain or benefit of your own haha
Gold at all time high, company updates every week, and yet BMXI goes.... down.

BMXI goes down. Not up. Even as Gold goes up 60%.

BMXI

blackhawks 22 분 전

Republicans want Musk to shut up about Social Security
Source: The Hill

03/20/25 6:00 AM ET

Senate Republicans want Elon Musk to stop talking about Social Security, and the Department of Government Efficiency to leave it alone. Musk’s statement that Social Securi

Countmein 23 분 전

Closed @ 28.11 on 1,088,472 volume

Count

HOMB

GoodGuyBill 24 분 전

A pumper used to be defined as a trader who buys a stock, hypes it up and then sells it while up, usually never believing in the hype they used to hype it up. Regardless of what you say, I am not a pumper. I believe in NWBO/DCVAX and Linda Powers (I have ample reason to). Several times I, regrettabl

NWBO

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

PureTech Health PLC (PRTC)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

PureTech Health PLC 정보

PRTC 최신 뉴스

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PRTC - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

PureTech Health PLC (PRTC) 시세

PureTech Health PLC (PRTC)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

PureTech Health PLC 정보

PRTC 최신 뉴스

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PRTC - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR